EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein

Laura Radić iD, Anna Offersgaard iD, Tereza Kadavá iD, Ian Zon, Joan Capella-Pujol, Fabian Mulder, Sylvie Koekkoek, Vera Spek, Ana Chumbe, Jens Bukh iD, Marit J van Gils iD, Rogier W Sanders und 5 weitere

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2420402122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Laura Radić und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Infection Prevention, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Center, Univers…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Viral Envelope Proteins, Hepacivirus, Hepatitis C Antibodies. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis C virus (HCV) currently causes about one million infections and 240,000 deaths worldwide each year. To reach the goal set by the World Health Organization of global HCV elimination by 2030, it is critical to develop a prophylactic vaccine. Broadly neutralizing antibodies (bNAbs) target the E1E2 envelope glycoproteins on the viral surface, can neutralize a broad range of the highly diverse circulating HCV strains, and are essential tools to inform vaccine design. However, bNAbs targeting a single E1E2 epitope might be limited in neutralization breadth, which can be enhanced by using combinations of bNAbs that target different envelope epitopes. We have generated 60 immunoglobulin G (IgG)-like bispecific antibodies (bsAbs) that can simultaneously target two distinct epitopes on E1E2. We combine non- or partially overlapping E1E2 specificities into three types of bsAbs, each containing a different hinge length. The majority of bsAbs shows retained or increased potency and breadth against a diverse panel of HCV pseudoparticles and HCV produced in cell culture compared to monospecific and cocktail controls. Additionally, we demonstrate that changes in the hinge length of bsAbs can alter the binding stoichiometry to E1E2. These results provide insights into the binding modes and the role of avidity in bivalent targeting of diverse E1E2 epitopes.This study illustrates how potential cooperative effects of HCV bNAbs can be utilized by strategically designing bispecific constructs. These HCV bsAbs can guide vaccine development and unlock novel therapeutic and prophylactic strategies against HCV and other (flavi)viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificViral Envelope ProteinsHepacivirusHepatitis C AntibodiesHumansEpitopesAntibodies, NeutralizingHepatitis CViral Hepatitis Vaccines

Stichwörter der Autor:innen

E1E2 envelope glycoproteinbNAbsbispecific antibodieshepatitis C virus (HCV)neutralization

Substanzen

Antibodies, BispecificViral Envelope Proteinsglycoprotein E2, Hepatitis C virusEpitopesAntibodies, NeutralizingHepatitis C AntibodiesE1 protein, Hepatitis C virusViral Hepatitis Vaccines

Autor:innen und Institutionen

  • Department of Medical Microbiology and Infection Prevention, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam 1105 AZ, the Netherlands.
  • Amsterdam Institute for Immunology and Infectious diseases, Amsterdam 1105 AZ, the Netherlands.
  • Copenhagen Hepatitis C Program, Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre 2650, Denmark.
  • Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen N 2200, Denmark.
  • Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CH, the Netherlands.
  • Netherlands Proteomics Center, Utrecht 3584 CH, the Netherlands.

ORCID-Profile: Laura Radić, Anna Offersgaard, Tereza Kadavá, Jens Bukh, Marit J van Gils, Victor C Yin, Albert J R Heck, Kwinten Sliepen, Janke Schinkel

Förderung

  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)

Zitieren

APA

Radić, L., Offersgaard, A., Kadavá, T., Zon, I., Capella-Pujol, J., Mulder, F., Koekkoek, S., Spek, V., Chumbe, A., Bukh, J., van Gils, M. J., Sanders, R. W., Yin, V. C., Heck, A. J. R., Gottwein, J. M., Sliepen, K., & Schinkel, J. (2025). Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2420402122

Vancouver

Radić L, Offersgaard A, Kadavá T, Zon I, Capella-Pujol J, Mulder F, et al. Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2420402122

BibTeX
@article{Radi2025,
  author = {Radić, Laura and Offersgaard, Anna and Kadavá, Tereza and Zon, Ian and Capella-Pujol, Joan and Mulder, Fabian and Koekkoek, Sylvie and Spek, Vera and Chumbe, Ana and Bukh, Jens and van Gils, Marit J and Sanders, Rogier W and Yin, Victor C and Heck, Albert J R and Gottwein, Judith M and Sliepen, Kwinten and Schinkel, Janke},
  title = {Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2420402122}
}
Kostenlos starten →